Molecular insights on basal-like breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 21-30

  Valentin, Mev Dominguez ^a   Da Silva, Sabrina Daniela ^b   Privat, Maud ^c   Alaoui Jamali, Moulay ^b   Bignon, Yves Jean ^c,d  

^a LUND UNIVERSITY   (Sweden)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Basal like breast cancer; BRCA1; Breast cancer; Prognosis; Transcriptional profiling; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CLINICAL FEATURE; DISEASE COURSE; EPIGENETICS; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINS, HAIR-SPECIFIC; KERATINS, TYPE I; KERATINS, TYPE II; RECEPTOR, ERBB-2; RECEPTORS, STEROID;

EID: 84863982081     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1934-z     Document Type: Review

References (84)

1. B Haupt JY Ro MR Schwartz 2010 Basal-like breast carcinoma: a phenotypically distinct entity Arch Pathol Lab Med 134 130 133 20073617
2. EA Rakha ME El-Sayed AR Green, et al. 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D
3. Presson AP, Yoon NK, Bagryanova L et al (2011) Protein expression based multimarker analysis of breast cancer samples. BMC Cancer. doi: 10.1186/1471-2407-11-230
4. Weigelt B, Reis-Filho JS (2010) Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res. doi: 10.1186/BCR2734
5. CM Perou T Sørlie MB Eisen, et al. 2000 Molecular portraits of human breast tumour Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
6. F Yehiely JV Moyano JR Evans, et al. 2006 Deconstructing the molecular portrait of basal-like breast cancer Trends Mol Med 12 11 537 544 17011236 10.1016/j.molmed.2006.09.004 1:CAS:528:DC%2BD28XhtFert7fL
7. T Sørlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas. 191367098
8. LA Niemeier DJ Dabbs S Beriwal, et al. 2010 Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation Mod Pathol 23 205 212 19898421 10.1038/modpathol.2009.159 1:CAS:528:DC%2BC3cXhsVyjtbg%3D
9. WJ Irvin Jr LA Carey 2008 What is triple-negative breast cancer? Eur J Cancer 44 2799 2805 19008097 10.1016/j.ejca.2008.09.034 1:CAS:528: DC%2BD1cXhsVKltr%2FE
10. EA Rakha SE Elsheikh MA Aleskandarany, et al. 2009 Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res 15 2302 2310 19318481 10.1158/1078-0432.CCR-08-2132 1:CAS:528:DC%2BD1MXjvVWltbs%3D
11. BP Schneider EP Winer WD Foulkes, et al. 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 8010 8018 19088017 10.1158/1078-0432.CCR-08-1208 1:CAS:528:DC%2BD1cXhsV2it73F Review
12. Gastaldi S, Comoglio PM, Trusolino L (2010) The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. doi: 10.1186/BCR2617
13. Herschkowitz JI, Simin K, Weigman VJ et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. doi: 10.1186/gb-2007-8-5-r76
14. BT Hennessy AM Gonzalez-Angulo K Stemke-Hale, et al. 2009 Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics Cancer Res 69 4116 4124 19435916 10.1158/0008-5472.CAN-08-3441 1:CAS:528:DC%2BD1MXlvFWltrg%3D
15. Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. doi: 10.1186/BCR2635
16. Herschkowitz JI, Zhao W, Zhang M et al (2011) Breast cancer special feature: comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA. doi: 10.1073/pnas.1018862108
17. P Farmer H Bonnefoi V Becette, et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 4660 4671 15897907 10.1038/sj.onc.1208561 1:CAS:528:DC%2BD2MXlvVGhsLc%3D
18. MA Lopez-Garcia FC Geyer M Lacroix-Triki, et al. 2010 Breast cancer precursors revisited: molecular features and progression pathways Histopathology 57 171 192 20500230 10.1111/j.1365-2559.2010.03568.x
19. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D
20. T Sorlie R Tibshirani J Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528: DC%2BD3sXlsFGntLk%3D
21. W Böcker B Bier G Freytag, et al. 1992 An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions Virchows Arch A Pathol Anat Histopathol 421 315 322 1384226 10.1007/BF01660978
22. E Korsching J Packeisen K Agelopoulos, et al. 2002 Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis Lab Investig 82 1525 1533 12429812 1:CAS:528:DC%2BD38XosVCnt70%3D
23. JR Choo TO Nielsen 2010 Biomarkers for basal-like breast cancer Cancers 2 1040 1065 10.3390/cancers2021040 1:CAS:528:DC%2BC3cXnslGitLY%3D
24. AI Khramtsov GF Khramtsova M Tretiakova, et al. 2010 Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome Am J Pathol 176 2911 2920 20395444 10.2353/ajpath.2010.091125
25. G Turashvili J Bouchal G Burkadze, et al. 2006 Wnt signaling pathway in mammary gland development and carcinogenesis Pathobiology 73 213 223 17314492 10.1159/000098207 1:CAS:528:DC%2BD2sXjsVOqtbY%3D
26. G Rubovszky N Udvarhelyi Z Horváth, et al. 2010 Triple-negative breast carcinoma-review of current literature Magy Onkol 54 325 335 21163763 10.1556/MOnkol.54.2010.4.6 Review
27. Honeth G, Bendahl PO, Ringnér M et al (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. doi: 10.1186/BCR2108
28. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 2568 2581 18487574 10.1200/JCO.2007.13.1748 Review
29. KA Kwei Y Kung K Salari, et al. 2010 Genomic instability in breast cancer: pathogenesis and clinical implications Mol Oncol 4 255 256 20434415 10.1016/j.molonc.2010.04.001 1:CAS:528:DC%2BC3cXhtVGlsLvL
30. A Bergamaschi YH Kim P Wang, et al. 2006 Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer Genes Chromosomes Cancer 45 1033 1040 16897746 10.1002/gcc.20366 1:CAS:528:DC%2BD28XpvFajsL4%3D
31. DJ Toft VL Cryns 2011 Minireview: basal-like breast cancer: from molecular profiles to targeted therapies Mol Endocrinol 25 199 211 20861225 10.1210/me.2010-0164 1:CAS:528:DC%2BC3MXitVygurk%3D Review
32. Letessier A, Sircoulomb F, Ginestier C et al (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. doi: 10.1186/1471-2407-6-245
33. J Adélaïde P Finetti I Bekhouche, et al. 2007 Integrated profiling of basal and luminal breast cancers Cancer Res 67 11565 11575 18089785 10.1158/0008-5472.CAN-07-2536
34. ZC Wang M Lin LJ Wei, et al. 2004 Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers Cancer Res 64 64 71 14729609 10.1158/0008-5472.CAN-03-2570 1:CAS:528: DC%2BD2cXkslyquw%3D%3D
35. F Liu X Chen A Allali-Hassan, et al. 2009 Discovery of a 2, 4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a J Med Chem 52 7950 7953 19891491 10.1021/jm901543m 1:CAS:528:DC%2BD1MXhtlOiurzN
36. Roll JD, Rivenbark AG, Jones WD et al (2008) DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. doi: 10.1186/1476-4598-7-15
37. P Parrella ML Poeta AP Gallo, et al. 2004 Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors Clin Cancer Res 10 5349 5354 15328171 10.1158/1078-0432.CCR-04-0555 1:CAS:528:DC%2BD2cXmvFSlt7o%3D
38. S Li M Rong B Iacopetta 2006 DNA hypermethylation in breast cancer and its association with clinicopathological features Cancer Lett 237 272 280 16029926 10.1016/j.canlet.2005.06.011 1:CAS:528:DC%2BD28XltF2qt7w%3D
39. Holm K, Hegardt C, Staaf J et al (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. doi: 10.1186/BCR2590
40. YK Bae A Brown E Garrett, et al. 2004 Hypermethylation in histologically distinct classes of breast cancer Clin Cancer Res 10 5998 6005 15447983 10.1158/1078-0432.CCR-04-0667 1:CAS:528:DC%2BD2cXnvVKqu7s%3D
41. N Dumont MB Wilson YG Crawford, et al. 2008 Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers Proc Natl Acad Sci USA 105 14867 14872 18806226 10.1073/pnas.0807146105 1:CAS:528:DC%2BD1cXht1aqur7P
42. SE Elsheikh AR Green EA Rakha, et al. 2009 Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome Cancer Res 69 3802 3809 19366799 10.1158/0008-5472.CAN-08-3907 1:CAS:528:DC%2BD1MXltFOks7g%3D
43. LJ Van't Veer H Dai MJ van de Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a
44. N Waddell J Arnold S Cocciardi, et al. 2010 Subtypes of familial breast tumours revealed by expression and copy number profiling Breast Cancer Res Treat 123 661 677 19960244 10.1007/s10549-009-0653-1
45. I Hedenfalk M Ringner A Ben-Dor, et al. 2003 Molecular classification of familial non-BRCA1/BRCA2 breast cancer Proc Natl Acad Sci USA 100 2532 2537 12610208 10.1073/pnas.0533805100 1:CAS:528:DC%2BD3sXitVais7Y%3D
46. T Sørlie 2004 Molecular portraits of breast cancer: tumour subtypes as distinct disease entities Eur J Cancer 40 2667 2675 15571950 10.1016/j.ejca.2004.08.021 Review
47. EA Rakha JS Reis-Filho IO Ellis 2008 Impact of basal-like breast carcinoma determination for a more specific therapy Pathobiology 75 95 103 18544964 10.1159/000123847
48. JJ Gorski RD Kennedy AM Hosey, et al. 2009 The complex relationship between BRCA1 and ERalpha in hereditary breast cancer Clin Cancer Res 15 1514 1518 19223511 10.1158/1078-0432.CCR-08-0640 1:CAS:528:DC%2BD1MXisVWku78%3D
49. PS Ray J Wang Y Qu, et al. 2010 FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer Cancer Res 70 3870 3876 20406990 10.1158/0008-5472.CAN-09-4120 1:CAS:528:DC%2BC3cXlvFyrtL8%3D
50. Y Yamamoto H Iwase 2010 Clinicopathological features and treatment strategy for triple-negative breast cancer Int J Clin Oncol 15 4 341 351 20632057 10.1007/s10147-010-0106-1
51. S Kobayashi 2008 Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance Breast Cancer 15 153 158 18311481 10.1007/s12282-008-0034-3
52. RC Millikan B Newman CK Tse PG Moorman, et al. 2008 Epidemiology of basal-like breast cancer Breast Cancer Res Treat 109 123 139 17578664 10.1007/s10549-007-9632-6
53. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D
54. R Ismail-Khan MM Bui 2010 A review of triple-negative breast cancer Cancer Control 17 173 176 20664514
55. Y Dong A Li J Wang, et al. 2010 Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer Cancer Res 70 5465 5474 20570903 10.1158/0008-5472.CAN-10-0173 1:CAS:528:DC%2BC3cXot1Wks70%3D
56. SM Rodríguez-Pinilla D Sarrió E Honrado, et al. 2007 Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J Clin Pathol 60 1006 1012 17105822 10.1136/jcp.2006.042143
57. SM Rodríguez-Pinilla D Sarrió E Honrado, et al. 2006 Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas Clin Cancer Res 12 1533 1539 16533778 10.1158/1078-0432.CCR-05-2281
58. H Li P Cherukuri N Li, et al. 2007 Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors Cancer Res 67 501 510 17234757 10.1158/0008-5472.CAN-05-4571 1:CAS:528:DC%2BD2sXmtVKlsQ%3D%3D
59. S Parry K Savage C Marchiò, et al. 2008 Nestin is expressed in basal-like and triple negative breast cancers J Clin Pathol 61 1045 1050 18641405 10.1136/jcp.2008.058750 1:STN:280:DC%2BD1crkvFGqtw%3D%3D
60. E Charafe-Jauffret F Monville F Bertucci, et al. 2007 Moesin expression is a marker of basal breast carcinomas Int J Cancer 121 1779 1785 17594689 10.1002/ijc.22923 1:CAS:528:DC%2BD2sXhtVyktb7P
61. SE Elsheikh AR Green EA Rakha, et al. 2008 Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype Br J Cancer 99 327 334 18612310 10.1038/sj.bjc.6604463 1:CAS:528: DC%2BD1cXosFWntrY%3D
62. SM Pinilla E Honrado D Hardisson, et al. 2006 Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer Breast Cancer Res Treat 99 85 90 16541313 10.1007/s10549-006-9184-1 1:CAS:528:DC%2BD28XnslShsbo%3D
63. K Savage MB Lambros D Robertson, et al. 2007 Caveolin 1 is overexpressed and basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, amplified in a subset of immunohistochemical, and in situ hybridization analysis Clin Cancer Res 13 90 101 17200343 10.1158/1078-0432.CCR- 06-1371 1:CAS:528:DC%2BD2sXotlel
64. K Savage S Leung SK Todd, et al. 2008 Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis Breast Cancer Res Treat 110 245 256 17912630 10.1007/s10549-007-9718-1 1:CAS:528:DC%2BD1cXmslygsr4%3D
65. S Lu K Simin A Khan, et al. 2008 Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance Clin Cancer Res 14 1050 1058 18281537 10.1158/1078-0432.CCR-07-4116 1:CAS:528:DC%2BD1cXhvF2gurc%3D
66. JS Reis-Filho D Steele S Di Palma, et al. 2006 Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue Mod Pathol 19 307 319 16424897 10.1038/modpathol. 3800542 1:CAS:528:DC%2BD28Xlt1equw%3D%3D
67. M Hasegawa S Moritani Y Murakumo, et al. 2008 CD109 expression in basal-like breast carcinoma Pathol Int 58 288 294 18429827 10.1111/j.1440-1827. 2008.02225.x
68. I Matos R Dufloth M Alvarenga, et al. 2005 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas Virchows Arch 447 688 694 16012853 10.1007/s00428-005-0010-7 1:CAS:528:DC%2BD2MXhtFKqt7zM
69. J Paredes N Lopes F Milanezi, et al. 2007 P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ Virchows Arch 450 73 80 17123107 10.1007/s00428-006-0334-y 1:CAS:528: DC%2BD2sXitlGjs70%3D
70. G Zabouo AM Imbert J Jacquemier, et al. 2009 CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines Breast Cancer Res 11 R1 19123925 10.1186/bcr2215
71. P Klingbeil R Natrajan G Everitt, et al. 2010 CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification Breast Cancer Res Treat 120 95 109 19350388 10.1007/s10549-009-0380-7 1:CAS:528:DC%2BC3cXntlarsQ%3D%3D
72. G Viale N Rotmensz P Maisonneuve, et al. 2009 Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 317 328 18839307 10.1007/s10549-008-0206-z 1:CAS:528:DC%2BD1MXntF2ntr8%3D
73. SA Mani J Yang M Brooks, et al. 2007 Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers Proc Natl Acad Sci USA 104 10069 10074 17537911 10.1073/pnas.0703900104 1:CAS:528:DC%2BD2sXmvVChtL4%3D
74. S Umemura M Shirane S Takekoshi, et al. 2009 Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome Br J Cancer 100 764 771 19259095 10.1038/sj.bjc.6604900 1:CAS:528: DC%2BD1MXisFenur0%3D
75. A Ribeiro-Silva LN Ramalho SB Garcia, et al. 2005 p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer Histopathology 47 458 466 16241993 10.1111/j.1365-2559.2005.02249.x 1:STN:280:DC%2BD2MrmsFKksg%3D%3D
76. EA Rakha TC Putti DM Abd El-Rehim, et al. 2006 Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation J Pathol 208 495 506 16429394 10.1002/path.1916 1:CAS:528:DC%2BD28XislCqt78%3D
77. JI Herschkowitz X He C Fan, et al. 2008 The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas Breast Cancer Res 10 5 R75 18782450 10.1186/bcr2142
78. H Kuroda F Ishida M Nakai, et al. 2008 Basal cytokeratin expression in relation to biological factors in breast cancer Hum Pathol 39 1744 1750 18755493 10.1016/j.humpath.2008.06.007 1:CAS:528:DC%2BD1cXhtlyltb%2FJ
79. O Walter M Prasad S Lu, et al. 2009 IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype Hum Pathol 40 1528 1533 19695680 10.1016/j.humpath.2009.05.005 1:CAS:528:DC%2BD1MXht1yjtLjK
80. I Skaland EA Janssen E Gudlaugsson, et al. 2009 The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer Cell Oncol 31 261 271 19633363 1:CAS:528:DC%2BD1MXovFSitbk%3D
81. H Zhang EA Rakha GR Ball, et al. 2010 The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer Breast Cancer Res Treat 121 41 51 19590950 10.1007/s10549-009-0450-x 1:CAS:528:DC%2BC3cXkvVymtL8%3D
82. XY Tang S Umemura H Tsukamoto, et al. 2010 Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer Pathol Res Pract 206 98 101 19608352 10.1016/j.prp.2009.06.010 1:CAS:528: DC%2BC3cXkvFyksr4%3D
83. JV Moyano JR Evans F Chen, et al. 2006 AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer J Clin Invest 116 261 270 16395408 10.1172/JCI25888 1:CAS:528:DC%2BD28XjslOgtA%3D%3D
84. SM Sitterding WR Wiseman CL Schiller, et al. 2008 AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas Ann Diagn Pathol 12 33 40 18164413 10.1016/j.anndiagpath.2007.02.004